3rd Quarter Results

5 November 2015

Year-To-Date and Q3 2015 Results

Financial Summary

                               YTD   2015              Q3   2015
                         $m    %   change       $m    %   change
                             CER1  Actual           CER1  Actual
     Total Revenue2  18,309     -     (8)    5,945   (2)    (10)

   Core3 Op. Profit   5,346     -     (7)    1,728     7     (2)
           Core EPS   $3.32     2     (6)    $1.03     8     (2)

Reported Op. Profit   3,026    31      22    1,170   137     116
       Reported EPS   $1.60    40      30    $0.61   237     203



  · Core EPS in the year to date up by 2% with Q3 Core EPS growth of 8%
  · Total Revenue stable in the year to date; Core Gross margin up by 1.0%
points to 83.3%
  · Resilient top-line performance underpinned continued investment in R&D. Core
R&D costs up by 18% in Q3,  reflecting the recent start of key Oncology trials
    · Core SG&A costs declined by 3% in the third quarter; increased by 2% in
the year to date
    · Upgraded FY 2015 Total Revenue and Core EPS guidance at constant exchange
rates

YTD Commercial Highlights
Growth platforms grew by 10%, representing 57% of Total Revenue:
1.   Respiratory: +8%, including 38% Q3 sales growth in Emerging Markets
2.   Brilinta/Brilique: +44%; Q3 US growth of 73%
3.   Diabetes: +26%, including 73% sales growth in Emerging Markets
4.   Emerging Markets: +12%. China sales growth of 17% (Q3 2015: +11%)
5.   Japan: +3%, with Q3 sales growth of 6%

Achieving Scientific Leadership: Progress since the prior results announcement

Regulatory    Brilinta - post-myocardial   infarction (MI) (PEGASUS trial) (US)
Approvals
Regulatory    PT003 - COPD (US)
Submission    Brilinta - acute coronary syndrome, post-MI (JP)
Acceptances   AZD9291 - lung cancer (JP)
Other Key     saxagliptin/dapaglifozin - type-2 diabetes   (US): Complete
Response Letter
Developments  AZD9291: Granted Priority Review by FDA and   Japanese MHLW FDA
Fast
              Track designation:

              anifrolumab - lupus, tremelimumab - mesothelioma, durvalumab -
head & neck
              cancer



Pascal Soriot, Chief Executive Officer, commenting on the results said:

"I'm pleased with our continued progress as we focus on executing our plans
across our growth platforms and pipeline. While we have more work to do on the
submission of saxagliptin/dapagliflozin combination in Diabetes, the significant
label update for Brilinta was accompanied by submission acceptances and
accelerated reviews in cancer, respiratory diseases and lupus. In particular,
our exciting Oncology portfolio maintained its momentum with four Priority
Review and Fast Track designations as well as supportive data at key congresses.

Our financial performance in the year to date, including an 8% increase in Core
EPS in the third quarter, underpinned today's upgrade to full-year guidance.
2016 will be a pivotal year in our strategic journey as we face the impact of
loss of exclusivity to Crestor in the US. Looking ahead however, the continued
performance of our growth platforms and upcoming launches will combine with our
increasing focus on costs and cash generation to help offset short-term
headwinds and return AstraZeneca to sustainable growth."

FY 2015 Guidance

All guidance is shown at CER1.

                                         New                            Old
Total          In   line with the prior year   A   low single-digit percent
Revenue                                       decline versus the prior year
Core            A   mid to high single-digit   A   low single-digit percent
Earnings   percent increase versus the prior      increase versus the prior
Per Share                               year                           year

Non-guidance information is also provided:
Based on average daily spot rates in the nine months to the end of September
2015, Total Revenue in FY 2015 is expected to decline by high single-digit
percent, with Core EPS expected to be broadly in line with FY 2014. In addition,
the majority of FY 2015 Externalisation Revenue is anticipated to have been
realised in the first half of the year. Core R&D costs are expected to grow at a
lower rate in the final quarter versus the year to date and the Company is
committed to reducing Core SG&A costs in FY 2015 versus the prior year, both in
terms of absolute value and relative to Total Revenue.

Pipeline: Forthcoming Major Newsflow

Q4    lesinurad - gout: Regulatory decision (US)
2015  brodalumab - psoriasis: Regulatory submission (US, EU)
      durvalumab - lung cancer: Data read-out
H1    PT003 - COPD: Regulatory decision (US)
2016  benralizumab - severe asthma: Data read-out
      Brilinta/Brilique - stroke: Data read-out
      AZD9291 - lung cancer: Regulatory decisions
      tremelimumab - mesothelioma: Data read-out
      Lynparza - breast cancer: Data read-out
H2    Brilinta/Brilique - peripheral arterial disease: Data read-out
2016  saxagliptin/dapaglifozin   - type-2 diabetes (EU): Regulatory decision
      durvalumab - head & neck cancer: Data read-out
      Lynparza - ovarian cancer: Data read-out
      CAZ AVI - serious infections: Regulatory decision (EU)

Notes
1.   All growth rates and guidance are shown at constant exchange rates (CER)
unless specified otherwise.
2.   Total Revenue defined as Product Sales and Externalisation Revenue. For
further details on the presentation of Total Revenue, see the
announcement (http://www.astrazeneca.com/Investors) published by the Company in
March 2015.
3.   See the Operating and Financial Review for a definition of Core financial
measures and a reconciliation of Core to Reported financial measures.
4.   The performance shown in this announcement covers the nine and three month
periods to 30 September 2015 (the year to date and the quarter respectively)
compared to the nine and three month periods to 30 September 2014 (the prior
year to date and the prior quarter respectively).

Results Presentation
A conference call for investors and analysts, hosted by management, will begin
at midday GMT today. Details can be accessed via www.astrazeneca.com/investors.

Reporting Calendar
The Company intends to publish its full-year financial results on 4 February
2016.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide.

Contacts at AstraZeneca

Media Enquiries
Esra Erkal-Paler  UK/Global  +44 20 7604 8030
Vanessa Rhodes    UK/Global  +44 20 7604 8037
Ayesha Bharmal    UK/Global  +44 20 7604 8034
Jacob Lund        Sweden     +46 8 553 260 20
Michele Meixell   US         +1 302 885 2677

Investor Enquiries
UK
Thomas Kudsk Larsen  Oncology             +44 7818 524185
Eugenia Litz         RIA                  +44 7884 735627
Nick Stone           CVMD                 +44 7717 618834
Craig Marks          Finance              +44 7881 615764
Christer Gruvris     Consensus Forecasts  +44 7827 836825
US
Lindsey Trickett     Oncology, ING        +1 240 543 7970
Mitchell Chan        Oncology             +1 240 477 3771
Toll-Free                                 +1 866 381 7277

Key: RIA - Respiratory, Inflammation & Autoimmunity, CVMD - Cardiovascular &
Metabolic Disease,
ING - Infection, Neuroscience & Gastrointestinal

Click on, or paste the following link into your web browser, to view the
associated PDF document.
http://www.rns-pdf.londonstockexchange.com/rns/1398F_1-2015-11-10.pdf